Monoclonal antibodies against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), ipilimumab, and programmed cell death protein 1 (PD-1), pembrolizumab and nivolumab, are approved for patients with advanced melanoma (1). Here, PDCD1 is linked to melanoma.